Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Morning Bell 18 January

Grady Wulff
January 18, 2024

Morning Bell 17 January

Grady Wulff
January 17, 2024

Morning Bell 16 January

Grady Wulff
January 16, 2024

Morning Bell 15 January

Sophia Mavridis
January 15, 2024

Weekly Wrap 15 December

Grady Wulff
December 15, 2023

Morning Bell 14 December

Grady Wulff
December 14, 2023

Morning Bell 13 December

Grady Wulff
December 13, 2023

Morning Bell 12 December

Grady Wulff
December 12, 2023

Morning Bell 11 December

Grady Wulff
December 11, 2023

Weekly Wrap 8 December

Sophia Mavridis
December 8, 2023